Skip to main content
. 2019 May 11;11(5):230. doi: 10.3390/pharmaceutics11050230

Table 4.

Antimicrobial efficacy of the optimized formulation (MM3).

Concentration (μg/mL) Zone of Inhibition in (cm)
Control * MM3
Staphylococcus aureus
1 1.63 ± 0.22 1.63 ± 0.26
10 2.44 ± 0.31 2.58 ± 0.18
100 3.52 ± 0.25 3.94 ± 0.24
Pseudomonas aeruginosa
1 1.82 ± 0.34 1.97 ± 0.16
10 2.77 ± 0.23 3.05 ± 0.21
100 4.05 ± 0.25 4.71 ± 0.29

* Control: Commercial eye drops of moxifloxacin.